{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:34:16Z","timestamp":1793892856069,"version":"4.8.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81870306"],"award-info":[{"award-number":["No. 81870306"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatocellular carcinoma (HCC) still ranks among the top cancers worldwide with high incidence and mortality. Due to abnormal activation of the PI3K\/AKT\/mTOR signalling pathway in HCC, targeting this pathway represents a potential therapeutic strategy. NVP-BEZ235 is a novel dual-targeted ATP-competitive PI3K\/mTOR inhibitor that has shown effective antitumor effects. In this study, we found that interleukin-6 (IL-6) was significantly increased after exposure to NVP-BEZ235, and we proposed a treatment in which an anti-IL-6 antibody was combined with NVP-BEZ235 for HCC. In vitro results revealed that targeted inhibition of IL-6 potentiated the antitumor effects of NVP-BEZ235 in HCC cells. The mechanism might be attributed to their synergistic inhibitory activity on the PI3K\/AKT\/mTOR signalling pathway. Furthermore, an in vivo study demonstrated that combined administration of NVP-BEZ235 and anti-IL-6 Ab reduced HCC tumour load more effectively than either NVP-BEZ235 or anti-IL-6 Ab treatment alone. These findings add guidance value to the analysis of HCC and provide a reference for clinical treatment.<\/jats:p>","DOI":"10.1038\/s41419-022-04583-5","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T07:03:13Z","timestamp":1644822193000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The synergistic antitumor effect of IL-6 neutralization with NVP-BEZ235 in hepatocellular carcinoma"],"prefix":"10.1038","volume":"13","author":[{"given":"Yao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuancong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7012-8913","authenticated-orcid":false,"given":"Jinzhen","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1119-3816","authenticated-orcid":false,"given":"Xianfeng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0473-7512","authenticated-orcid":false,"given":"Weihua","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"issue":"Suppl 1","key":"4583_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/hep.31288","volume":"73","author":"KA McGlynn","year":"2021","unstructured":"McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73 Suppl 1:4\u201313.","journal-title":"Hepatology"},{"key":"4583_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Prim. 2021;7:6.","journal-title":"Nat Rev Dis Prim"},{"key":"4583_CR3","doi-asserted-by":"publisher","first-page":"188314","DOI":"10.1016\/j.bbcan.2019.188314","volume":"1873","author":"D Anwanwan","year":"2020","unstructured":"Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 2020;1873:188314.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"4583_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s12072-018-9919-1","volume":"13","author":"T Couri","year":"2019","unstructured":"Couri T, Pillai A. Goals and targets for personalized therapy for HCC. Hepatol Int. 2019;13:125\u201337.","journal-title":"Hepatol Int"},{"key":"4583_CR5","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jhep.2019.09.010","volume":"72","author":"S Faivre","year":"2020","unstructured":"Faivre S, Rimassa L, Richard SF. Molecular therapies for HCC: Looking outside the box. J Hepatol. 2020;72:342\u201352.","journal-title":"J Hepatol"},{"key":"4583_CR6","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn R, Qin S, Han KHIK, Piscaglia F. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"4583_CR7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","volume":"15","author":"J Llovet","year":"2018","unstructured":"Llovet J, Montal R, Sia D, Finn R. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15:599\u2013616.","journal-title":"Nat Rev Clin Oncol"},{"key":"4583_CR8","first-page":"153","volume":"407","author":"M Aoki","year":"2017","unstructured":"Aoki M, Fujishita T. Oncogenic roles of the PI3K\/AKT\/mTOR axis. Curr Top Microbiol Immunol. 2017;407:153\u201389.","journal-title":"Curr Top Microbiol Immunol"},{"key":"4583_CR9","doi-asserted-by":"publisher","first-page":"10839","DOI":"10.18632\/aging.102488","volume":"11","author":"J Chen","year":"2019","unstructured":"Chen J, Chen J, Huang J, Li Z. HIF-2\u03b1 upregulation mediated by hypoxia promotes NAFLD-HCC progression by activating lipid synthesis via the PI3K-AKT-mTOR pathway. Aging. 2019;11:10839\u201360.","journal-title":"Aging"},{"key":"4583_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09598-9","volume":"10","author":"A Iershov","year":"2019","unstructured":"Iershov A, Nemazanyy I, Alkhoury C, Girard M, Barth E, Cagnard N, et al. The class 3 PI3K coordinates autophagy and mitochondrial lipid catabolism by controlling nuclear receptor PPARalpha. Nat Commun. 2019;10:1566.","journal-title":"Nat Commun"},{"key":"4583_CR11","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1158\/1535-7163.MCT-13-0099","volume":"12","author":"W Wen","year":"2013","unstructured":"Wen W, Han T, Chen C, Huang L. Cyclin G1 expands liver tumor-initiating cells by Sox2 induction via Akt\/mTOR signaling. Mol Cancer Ther. 2013;12:1796\u2013804.","journal-title":"Mol Cancer Ther"},{"key":"4583_CR12","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","volume":"834","author":"YT Lee","year":"2018","unstructured":"Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: Treating cancer with specificity. Eur J Pharm. 2018;834:188\u201396.","journal-title":"Eur J Pharm"},{"key":"4583_CR13","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/978-981-15-4494-1_14","volume":"1255","author":"L Duncan","year":"2020","unstructured":"Duncan L, Shay C, Teng Y. PI3K isoform-selective inhibitors in cancer. Adv Exp Med Biol. 2020;1255:165\u201373.","journal-title":"Adv Exp Med Biol"},{"key":"4583_CR14","doi-asserted-by":"publisher","first-page":"883","DOI":"10.2174\/1568026620666200224101808","volume":"20","author":"NE Uko","year":"2020","unstructured":"Uko NE, Guner OF, Matesic DF, Bowen JP. Akt pathway inhibitors. Curr Top Med Chem. 2020;20:883\u2013900.","journal-title":"Curr Top Med Chem"},{"key":"4583_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.semcancer.2019.07.009","volume":"59","author":"AS Alzahrani","year":"2019","unstructured":"Alzahrani AS. PI3K\/Akt\/mTOR inhibitors in cancer: At the bench and bedside. Semin Cancer Biol. 2019;59:125\u201332.","journal-title":"Semin Cancer Biol"},{"key":"4583_CR16","doi-asserted-by":"publisher","first-page":"682","DOI":"10.7150\/ijbs.37592","volume":"16","author":"B Ruan","year":"2020","unstructured":"Ruan B, Liu W, Chen P, Cui R, Li Y, Ji M, et al. NVP-BEZ235 inhibits thyroid cancer growth by p53-dependent\/independent p21 upregulation. Int J Biol Sci. 2020;16:682\u201393.","journal-title":"Int J Biol Sci"},{"key":"4583_CR17","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.3390\/ijms19113546","volume":"19","author":"CM Hsu","year":"2018","unstructured":"Hsu CM, Lin PM, Lin HC, Tsai YT, Tsai MS, Li SH, et al. NVP-BEZ235 attenuated cell proliferation and migration in the squamous cell carcinoma of oral cavities and p70S6K inhibition mimics its effect. Int J Mol Sci. 2018;19:3546.","journal-title":"Int J Mol Sci"},{"key":"4583_CR18","doi-asserted-by":"publisher","first-page":"6111","DOI":"10.2147\/OTT.S172957","volume":"11","author":"L Li","year":"2018","unstructured":"Li L, Zhang S, Xie D, Chen H, Zheng X, Pan D. Dual inhibitor of PI3K and mTOR (NVP-BEZ235) augments the efficacy of fluorouracil on gastric cancer chemotherapy. Onco Targets Ther. 2018;11:6111\u20138.","journal-title":"Onco Targets Ther"},{"key":"4583_CR19","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.3390\/molecules25102454","volume":"25","author":"CC Yu","year":"2020","unstructured":"Yu CC, Huang SY, Chang SF, Liao KF, Chiu SC. The synergistic anti-cancer effects of NVP-BEZ235 and regorafenib in hepatocellular carcinoma. Molecules. 2020;25:2454.","journal-title":"Molecules"},{"key":"4583_CR20","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/liv.12126","volume":"33","author":"MM Kirstein","year":"2013","unstructured":"Kirstein MM, Boukouris AE, Pothiraju D, Buitrago-Molina LE, Marhenke S, Schutt J, et al. Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma. Liver Int. 2013;33:780\u201393.","journal-title":"Liver Int"},{"key":"4583_CR21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.coph.2015.05.017","volume":"23","author":"AK Stark","year":"2015","unstructured":"Stark AK, Sriskantharajah S, Hessel EM, Okkenhaug K. PI3K inhibitors in inflammation, autoimmunity and cancer. Curr Opin Pharm. 2015;23:82\u201391.","journal-title":"Curr Opin Pharm"},{"key":"4583_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.trim.2015.06.001","volume":"33","author":"S Ustun","year":"2015","unstructured":"Ustun S, Lassnig C, Preitschopf A, Mikula M, Muller M, Hengstschlager M, et al. Effects of the mTOR inhibitor everolimus and the PI3K\/mTOR inhibitor NVP-BEZ235 in murine acute lung injury models. Transpl Immunol. 2015;33:45\u201350.","journal-title":"Transpl Immunol"},{"key":"4583_CR23","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.pharmthera.2013.12.004","volume":"142","author":"J Polivka Jr.","year":"2014","unstructured":"Polivka J Jr., Janku F. Molecular targets for cancer therapy in the PI3K\/AKT\/mTOR pathway. Pharm Ther. 2014;142:164\u201375.","journal-title":"Pharm Ther"},{"key":"4583_CR24","doi-asserted-by":"publisher","first-page":"491.","DOI":"10.3390\/cancers12020491","volume":"12","author":"M Dimri","year":"2020","unstructured":"Dimri M, Satyanarayana A. Molecular signaling pathways and therapeutic targets in hepatocellular carcinoma. Cancers. 2020;12:491.","journal-title":"Cancers"},{"key":"4583_CR25","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","volume":"391","author":"F Alejandro","year":"2018","unstructured":"Alejandro F, Mar\u00eda R, Jordi B. Hepatocellular carcinoma. Lancet. 2018;391:1301\u201314.","journal-title":"Lancet"},{"key":"4583_CR26","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.pharmthera.2017.02.010","volume":"173","author":"R Dutta","year":"2017","unstructured":"Dutta R, Mahato RI. Recent advances in hepatocellular carcinoma therapy. Pharm Ther. 2017;173:106\u201317.","journal-title":"Pharm Ther"},{"key":"4583_CR27","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1200\/JCO.2014.59.0018","volume":"34","author":"ML Patricia","year":"2016","unstructured":"Patricia ML. Inhibition of the PI3K\/AKT\/mTOR pathway in solid tumors. J Clin Oncol. 2016;34:3803\u201315.","journal-title":"J Clin Oncol"},{"key":"4583_CR28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fonc.2014.00064","volume":"4","author":"C Porta","year":"2014","unstructured":"Porta C, Paglino C, Mosca A. Targeting PI3K\/Akt\/mTOR signaling in cancer. Front Oncol. 2014;4:64.","journal-title":"Front Oncol"},{"key":"4583_CR29","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.ejmech.2016.01.012","volume":"109","author":"V Asati","year":"2016","unstructured":"Asati V, Mahapatra DK, Bharti SK. PI3K\/Akt\/mTOR and Ras\/Raf\/MEK\/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives. Eur J Med Chem. 2016;109:314\u201341.","journal-title":"Eur J Med Chem"},{"key":"4583_CR30","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.jhep.2016.02.004","volume":"64","author":"D Schmidt-Arras","year":"2016","unstructured":"Schmidt-Arras D, Rose-John S. IL-6 pathway in the liver: From physiopathology to therapy. J Hepatol. 2016;64:1403\u201315.","journal-title":"J Hepatol"},{"key":"4583_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.canlet.2020.09.025","volume":"497","author":"PK Wan","year":"2021","unstructured":"Wan PK, Leung TH, Siu MK, Mo XT, Tang HW, Chan KK, et al. HPV-induced Nurr1 promotes cancer aggressiveness, self-renewal, and radioresistance via ERK and AKT signaling in cervical cancer. Cancer Lett. 2021;497:14\u201327.","journal-title":"Cancer Lett"},{"key":"4583_CR32","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.2147\/IJN.S290731","volume":"16","author":"Y Hu","year":"2021","unstructured":"Hu Y, Zhang K, Zhu X, Zheng X, Wang C, Niu X, et al. Synergistic inhibition of drug-resistant colon cancer growth with PI3K\/mTOR dual inhibitor BEZ235 and nano-emulsioned paclitaxel via reducing multidrug resistance and promoting apoptosis. Int J Nanomed. 2021;16:2173\u201386.","journal-title":"Int J Nanomed"},{"key":"4583_CR33","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/978-3-030-20301-6_9","volume":"1152","author":"DW Edwardson","year":"2019","unstructured":"Edwardson DW, Parissenti AM, Kovala AT. Chemotherapy and inflammatory cytokine signalling in cancer cells and the tumour microenvironment. Adv Exp Med Biol. 2019;1152:173\u2013215.","journal-title":"Adv Exp Med Biol"},{"key":"4583_CR34","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13058-018-1062-3","volume":"20","author":"KD van der Willik","year":"2018","unstructured":"van der Willik KD, Koppelmans V, Hauptmann M, Compter A, Ikram MA, Schagen SB. Inflammation markers and cognitive performance in breast cancer survivors 20 years after completion of chemotherapy: A cohort study. Breast Cancer Res: BCR. 2018;20:135.","journal-title":"Breast Cancer Res: BCR"},{"key":"4583_CR35","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1016\/S1470-2045(14)70263-3","volume":"15","author":"CI Diakos","year":"2014","unstructured":"Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15:e493\u2013503.","journal-title":"Lancet Oncol"},{"key":"4583_CR36","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.smim.2014.01.001","volume":"26","author":"K Taniguchi","year":"2014","unstructured":"Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol. 2014;26:54\u201374.","journal-title":"Semin Immunol"},{"key":"4583_CR37","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","volume":"141","author":"X Yao","year":"2014","unstructured":"Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharm Ther. 2014;141:125\u201339.","journal-title":"Pharm Ther"},{"key":"4583_CR38","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1165\/rcmb.2010-0479OC","volume":"46","author":"K Matsumoto","year":"2012","unstructured":"Matsumoto K, Asai Y, Fukuyama S, Kan OK, Matsunaga Y, Noda N, et al. IL-6 induced by double-stranded RNA augments allergic inflammation via suppression of Foxp3+ T-cell\/IL-10 axis. Am J Respiratory Cell Mol Biol. 2012;46:740\u20137.","journal-title":"Am J Respiratory Cell Mol Biol"},{"key":"4583_CR39","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1042\/CS20130110","volume":"125","author":"C Hubeau","year":"2013","unstructured":"Hubeau C, Kubera JE, Masek-Hammerman K, Williams CM. Interleukin-6 neutralization alleviates pulmonary inflammation in mice exposed to cigarette smoke and poly(I:C). Clin Sci. 2013;125:483\u201393.","journal-title":"Clin Sci"},{"key":"4583_CR40","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.bbrc.2009.12.081","volume":"391","author":"N Kubota","year":"2010","unstructured":"Kubota N, Ebihara T, Matsumoto M, Gando S, Seya T. IL-6 and IFN-alpha from dsRNA-stimulated dendritic cells control expansion of regulatory T cells. Biochem Biophys Res Commun. 2010;391:1421\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"4583_CR41","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1158\/1078-0432.CCR-20-2821","volume":"27","author":"A Patnaik","year":"2021","unstructured":"Patnaik A, Yap TA, Chung HC, de Miguel MJ, Bang YJ, Lin CC, et al. Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: The PACT phase Ia\/Ib trial. Clin Cancer Res. 2021;27:1267\u201377.","journal-title":"Clin Cancer Res"},{"key":"4583_CR42","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","volume":"396","author":"EA Mittendorf","year":"2020","unstructured":"Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): A randomised, double-blind, phase 3 trial. Lancet. 2020;396:1090\u20131100.","journal-title":"Lancet"},{"key":"4583_CR43","doi-asserted-by":"publisher","first-page":"5165.","DOI":"10.3390\/ijms21145165","volume":"21","author":"M Bonelli","year":"2020","unstructured":"Bonelli M, Terenziani R, Zoppi S, Fumarola C, La Monica S, Cretella D, et al. Dual inhibition of CDK4\/6 and PI3K\/AKT\/mTOR signaling impairs energy metabolism in MPM cancer cells. Int J Mol Sci. 2020;21:5165.","journal-title":"Int J Mol Sci"},{"key":"4583_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78646-y","volume":"10","author":"Y Fujimoto","year":"2020","unstructured":"Fujimoto Y, Morita TY, Ohashi A, Haeno H, Hakozaki Y, Fujii M, et al. Combination treatment with a PI3K\/Akt\/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells. Sci Rep. 2020;10:21762.","journal-title":"Sci Rep"},{"key":"4583_CR45","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1158\/2159-8290.CD-11-0218","volume":"1","author":"PK Vogt","year":"2011","unstructured":"Vogt PK, Hart JR. PI3K and STAT3: A new alliance. Cancer Discov. 2011;1:481\u20136.","journal-title":"Cancer Discov"},{"key":"4583_CR46","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1158\/1078-0432.CCR-18-2484","volume":"25","author":"J Xu","year":"2019","unstructured":"Xu J, Zhang Y, Jia R, Yue C, Chang L, Liu R, et al. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: An open-label, dose escalation, and expansion study. Clin Cancer Res. 2019;25:515\u201323.","journal-title":"Clin Cancer Res"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04583-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04583-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04583-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T15:07:29Z","timestamp":1669302449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04583-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["4583"],"URL":"https:\/\/doi.org\/10.1038\/s41419-022-04583-5","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,14]]},"assertion":[{"value":"22 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal work was conducted according to relevant national and international guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"146"}}